BCL2 and B-cell chronic lymphocytic leukemia: Indeed, we found that FTY720 simultaneously reduced T163pMCL-1, S70pBCL-2, S112pBAD, S184pBAX, and MCL-1 levels (Figure 13C), rewired dependence from MCL-1 to BCL-2 (Figure 13D), and thereby resensitized venetoclax-resistant primary CLL cells to venetoclax (Figure 13E).